Hormones, Peptides & Personalized Protocols

A Mayo Clinic study presented at ENDO 2025 shows that combining menopause hormone therapy with tirzepatide results in significantly greater weight loss—17% on average versus 14% with tirzepatide alone—with 45% of women losing 20% or more of their body weight.

New advances in menopausal hormone therapy focus on individualized dosing, safer delivery methods, and biomarker-guided protocols for better outcomes with fewer risks.

Despite claims of greater safety or effectiveness, compounded bioidentical hormone therapies lack FDA oversight and robust clinical evidence—and they carry the same risks as traditional hormone treatments, according to expert reviews.

Studies indicate that hormone therapy may enhance cholesterol profiles and promote better heart health after menopause.